My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AlloVir, Inc. - Common Stock (NQ:ALVR)

9.810 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AlloVir, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of AlloVir, Inc. (ALVR) Investors

January 22, 2024

From Kirby McInerney LLP

Via Business Wire

ROSEN, A LONGSTANDING LAW FIRM, Encourages AlloVir, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR

January 22, 2024

From Rosen Law Firm

Via Business Wire

ALLOVIR, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against AlloVir, Inc. (NASDAQ: ALVR)

January 22, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

AlloVir Inc. (NASDAQ: ALVR) Near the Top of Equities by Percentage Gain on 8/21

August 21, 2023

Via Investor Brand Network

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

November 16, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Reports Third Quarter 2023 Financial Results

November 02, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir to Present at Upcoming Investor Conferences

August 28, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Reports Second Quarter 2023 Financial Results

August 03, 2023

From AlloVir, Inc.

Via Business Wire

MarketBeat Week in Review – 7/10 - 7/14

July 15, 2023

As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week

Via MarketBeat

Topics Economy

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

July 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

Via MarketBeat

Topics Retirement

AlloVir Announces Pricing of Public Offering of Common Stock

June 21, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Proposed Public Offering of Common Stock

June 21, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)

June 05, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer

May 16, 2023

From AlloVir

Via Business Wire

AlloVir Reports First Quarter 2023 Financial Results

May 04, 2023

From AlloVir

Via Business Wire

AlloVir to Present at the BofA Securities 2023 Health Care Conference

May 01, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023

April 26, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors

February 23, 2023

From AlloVir

Via Business Wire

AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook

February 15, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

February 15, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir to Participate in the SVB Securities Global Biopharma Conference

February 01, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

January 09, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From AlloVir, Inc.

Via Business Wire

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition

December 10, 2022

From AlloVir

Via Business Wire

AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 15, 2022

From AlloVir

Via Business Wire

Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting

November 03, 2022

From AlloVir, Inc.

Via Business Wire

AlloVir Reports Third Quarter 2022 Financial Results

November 03, 2022

From AlloVir, Inc.

Via Business Wire

AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

August 31, 2022

From AlloVir, Inc.

Via Business Wire

AlloVir Reports Second Quarter 2022 Financial Results

August 04, 2022

From AlloVir, Inc.

Via Business Wire

AlloVir Announces $126.6 Million Registered Direct Offering

July 27, 2022

From AlloVir, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.